

Time to move forward: Challenges and Research Opportunities for Lung Cancer Screening and Early Detection in Europe

11 – 12 February 2021

Berlin, Germany

Thursday, 11 February 2021

08.30 – 08.45 Registration

08.45 – 09.00 Introduction – Jan van Meerbeeck, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any progress?

09.00 – 09.20 Two years after NELSON: are the data mature yet? – Harry De Koning, NL

09.20 – 09.40 Presentation of ESTI initiative (Lung Cancer Screening Certification Project) – tbc

09.40 – 10.00 Discussion

10.00 – 10.30 Coffee break

10.30 – 11.30 Break-out session I

1 per country/region: What is currently ongoing in Europe?

- Screening initiatives after the ERS research seminar 2018: an update
- How will smoking cessation be integrated into lung cancer screening in your lung cancer screening program?

11.30 – 12.00 Report to the plenary session and discussion

12.00 – 13.00 Lunch break

Session 2: The time to implement is now

13.00 – 13.20 Making research findings more powerful for clinical use – Sabina De Geest, CH

13.20 – 13.40 Psychosocial consequences: life before and after a positive screening result – tbc

13.40 – 14.00 Targeting the hard to reach: will research on the Achilles heel of lung cancer screening defy its success? – tbc

14.00 – 14.30 Discussion

14.30 – 16.30 Break out session 2: presentation of research projects in Europe

- **Group 1:** Ct-scan screening implementation research
- **Group 2:** Non-imaging early detection research
- **Group 3:** ERS-task force on handling of screen detected nodules

16.30 – 17.00 Coffee break

Session 3: The world does not stand still: evolution in imaging and treatment

- 17.00 – 17.20 Is ultra-low-dose ready for practice? – Mario Silva, IT
- 17.20 – 17.40 Research opportunities in nodule handling: robotic surgery and beyond – tbc
- 17.40 – 18.00 Research opportunities in nodule handling: stereotactic ablation and beyond – tbc
- 18.00 – 18.30 Discussion

Friday, 12 February 2021

Session 4: Early detection biomarkers: ready for implementation in screening?

- 09.00 – 09.20 Biomarker performance and pathways to clinical utility – Pierre Massion, USA
- 09.20 – 09.40 Genomic screening: myths, promises and achievements – Joanna Chorostowska-Wynimko, PL
- 09.40 – 10.00 VOC's for lung cancer screening: where are we now? – tbc
- 10.00 – 10.30 Discussion
- 10.30 – 11.00 *Coffee break*

11.00 – 12.00 Report from break out session II

- Group 1 + discussion 20'
- Group 2 + discussion 20'
- Group 3 + discussion 20'

Session 5: Taking research forward in the ERS

- 12.00 – 12.20 What is the optimal design for trials incorporating biomarkers and CT-scan screening
– Luis M. Montuenga, ES
- 12.20 – 12.40 Agenda for an ERS clinical research collaboration – Jan van Meerbeeck, BE
- 12.40 – 13.00 Remarks, wrap up and action points
- 13.00 – 14.00 Lunch